Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

Melanoma research - 1 Apr 2015

Seremet Teofila, Lienard Danielle, Suppa Mariano, Trepant Anne-Laure, Rorive Sandrine, Woff Erwin, Cuylits Nicolas, Jansen Yanina, Schreuer Max, Del Marmol Véronique, Neyns Bart

Abstract excerpt

The treatment of locally advanced metastasized melanoma is challenging because there is no level 1 evidence to guide clinical decision-making. Moreover, the treatment options available fail to improve overall survival and are associated with considerable morbidity. Here, we show that systemic tre...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Drug Substitution
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Vemurafenib

Source

Identifiers

PMID: 25643238
DOI: 10.1097/CMR.0000000000000145

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25643238-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.PMID 25643238Read ↗

First line treatment of BRAF mutated advanced melanoma: Does one size fit all?Semantic proximity Read ↗

Recent developments in the medical and surgical treatment of melanoma.Semantic proximity Read ↗

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.Semantic proximity Read ↗

Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?Semantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.Semantic proximity Read ↗

Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.Semantic proximity Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.